摘要
目的:研究分析特异性免疫对于变应性鼻炎合并哮喘的治疗效果和在临床上广泛应用是否安全。方法:所有患者按照简单随机分组分成免疫和对症两个大组,分别接受标准化屋尘螨变应原制剂和对症性药物治疗,评价研究开始前、治疗1年、2年、3年这4个时间点的病症严重程度和使用药物情况,并详细地记录在整个研究过程中所产生的的不良症状现象。结果:两组在经过相应不同的治疗之后其鼻部和哮喘症状评分和使用药物评分都表现出非常明显的下降趋势(P<0.05),对症组的各项评分得出的数据都明显比免疫组要高(P<0.05);免疫组最终得到的不良症状发生几率远远比对症组要低(P<0.05)。结论:对变应性鼻炎合并哮喘患者使用特异性免疫治疗的效果明显比其使用对症性药物更好,因此其更适用于临床上的大量使用。
Objective:To study and analyze the therapeutic effect of specific immunity on allergic rhinitis with asthma and whether it is safe to use it widely in clinic.Methods:All patients were simple random grouping divided into two groups:immune group and symptomatic group.They were treated with standardized house dust mite allergen preparations and symptomatic drugs respectively.The severity of the disease and the use of drugs were evaluated before the start of the study,one year,two years and three years after the treatment.The adverse symptoms during the whole study were recorded in detail.Results:The nasal and asthmatic symptom scores and drug use scores of the two groups showed a significant downward trend(P<0.05),and the data of the symptomatic group were significantly higher than those of the immune group(P<0.05);the probability of adverse symptoms in the immune group was much lower than that in the symptomatic group(P<0.05).Conclusion:Specific immunotherapy for allergic rhinitis with asthma is better than symptomatic drugs,so it is more suitable for clinical use.
作者
杨栋
邢雁飞
寻满湘
YANG Dong;XING Yanfei;XIU Manxiang(Hospital of Traditional Chinese Medicine in Jiading District of Shanghai,Shanghai Jiading 201800,China)
出处
《河北医学》
CAS
2019年第2期255-259,共5页
Hebei Medicine
基金
上海市卫生和计划生育委员会中医药科研专项
(编号:2016LP005)
